# OnCo record aura3 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/aura3/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "aura3", "NCT02151981" ;
  schema:name "AURA3"@en ;
  schema:description "Proved that a drug designed against the specific mutation that causes resistance works far better than chemotherapy, and made resistance testing part of routine lung cancer care."@en ;
  schema:url <https://onco.cc/trials/aura3/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02151981>, <https://doi.org/10.1056/NEJMoa1612674>, <https://www.nice.org.uk/guidance/ta653> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/tki-term/>, <https://onco.cc/terms/brain-metastases/> ;
  onco:trials <https://onco.cc/trials/flaura/> .